Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Gynecol Oncol. 2011 Jul 12;123(1):19–26. doi: 10.1016/j.ygyno.2011.06.022

Figure 1.

Figure 1

Figure 1

Kaplan-Meier progression-free survival (PFS) and overall survival (OS) distributions for persistent/recurrent epithelial ovarian cancer or primary peritoneal cancer (A). Kaplan-Meier plots for progression-free survival (PFS)(B) and overall survival (OS)(C) by tumor expression of cyclin D1 categorized as negative or positive, and for progression-free survival by tumor expression of pAKT (D), pmTOR (E), pp70-S6K (F) categorized as negative or positive, or p4E-BP1 (G) categorized as low (<50% positive tumor cells) or positive (≥50% positive tumor cells) following temsirolimus treatment. Suggestive associations were assessed by logrank test with p<0.05.